Cover Image

Subcutaneous anakinra in the management of refractory MIS-C in France

IntroductionMultisystemic inflammatory syndrome in children (MIS-C) is a therapeutic emergency and can lead to myocardial dysfunction (17%-75%) and heart failure (52%-53%). Intravenous immunoglobulins (IVIG) and corticosteroids (CST) have been validated for the management of this condition. Recent r...

Full description

Saved in:

Bibliographic Details
Main Authors:	Perrine Dusser (Author), Alexandre Belot (Author), Fanny Bajolle (Author), Charlotte Kevorkian-Verguet (Author), Ulrich Meinzer (Author), Frédéric Huet (Author), Soizic Tiriau (Author), Isabelle Kone-paut (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Hypofertility in Muckle Wells syndrome and treatment with IL-1 targeting drugs
by: Tran Tu-Anh, et al.
Published: (2011)

Multisystem inflammatory syndrome in children during the COVID-19 waves: data from the Juvenile Inflammatory Rheumatism cohort
by: Robin Kechiche, et al.
Published: (2023)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023)

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
by: Şengül Çaǧlayan, et al.
Published: (2022)

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study
by: Francesco Licciardi, et al.
Published: (2023)

Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
by: Francesco La Torre, et al.
Published: (2023)

Long-term control of refractory Schnitzler syndrome with anakinra: a case report
by: Hsien-Yi Chiu, et al.
Published: (2010)

Usefulness of interleukin 1 receptor antagonist (anakinra) in refractory post-pericardiotomy syndrome
by: Marta Flores Fernández, et al.
Published: (2021)

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra
by: Alessandro Gambacorta, et al.
Published: (2020)

Rationale and efficacy of interleukin-1 targeting in pediatric Erdheim- Chester disease
by: Kone-Paut I, et al.
Published: (2011)

Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic
by: Adrien Schvartz, et al.
Published: (2020)

Application of anakinra in inflammatory dermatoses
by: Xiaomei YOU, et al.
Published: (2024)

Continuous IV infusion of anakinra
by: Brittney N. Saunders, et al.
Published: (2023)

Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions
by: Dima Chbeir, et al.
Published: (2018)

Survey of off-label anti-IL1 treatments in France: preliminary data
by: Koné-Paut I, et al.
Published: (2011)

Possibilities for the use of anakinra in COVID-19
by: V. A. Otdelenov, et al.
Published: (2020)

Football et identité : en France et en Allemagne
by: Ulrich Pfeil
Published: (2010)

Effect of anakinra on arthropathy in CINCA/NOMID syndrome
by: Kaneko Utako, et al.
Published: (2010)

Anakinra Therapy for Non-cancer Inflammatory Diseases
by: Giulio Cavalli, et al.
Published: (2018)

Efficacy of anakinra as a treatment for recurrent pericarditis
by: Sara Murias Loza, et al.
Published: (2018)

Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis
by: A. Lo Gullo, et al.
Published: (2017)

Intravenous administration of anakinra in children with macrophage activation syndrome
by: Omkar Phadke, et al.
Published: (2021)

Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases
by: Giulio Cavalli, et al.
Published: (2019)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
by: Mahamid M, et al.
Published: (2011)

Anakinra and hepatotoxicity in pediatric rheumatology: a case series
by: Frederico Rajão Martins, et al.
Published: (2023)

Anakinra for secondary amyloidosis in an adolescent with FMF and Behcet Disease
by: Bilginer Y, et al.
Published: (2008)

Potential association between M694V homozygous mutation in familial Mediterranean fever and eosinophilic intestinal inflammation: a pediatric case series
by: G. Dingulu, et al.
Published: (2024)

Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia
by: Elizabeth D. Slaney, et al.
Published: (2024)

Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis
by: Sullender RT, et al.
Published: (2024)

Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights
by: Bing‐Bing Yang, et al.
Published: (2019)

Mis dos rostros
by: Dunis Argüelles Guevara
Published: (2023)

The mis-rule of three
by: Warden, Florence, 1857-1929

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy
by: A Aiello, et al.
Published: (2023)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
by: Santa-María V, et al.
Published: (2011)

The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis
by: L. Riente
Published: (2011)

Efficacy of Anakinra Treatment in two Moroccan Patients With Mevalonate Kinase Deficiency
by: Manal Souali, et al.
Published: (2023)

The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats
by: Alevtina Ersoy, et al.
Published: (2023)

Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
by: Šárka Fingerhutová, et al.
Published: (2022)

Eficacia de anakinra como tratamiento de la pericarditis recurrente
by: Sara Murias Loza, et al.
Published: (2018)

Evaluation of the Versius Robotic Surgical System for Procedures in Small Cavities
by: Marit Kayser, et al.
Published: (2022)